Taken together, the STZ-induced mice treated with SA could have normalized hyperlipidemia, including blood TG and TC levels, by a reduction in the expression levels of FAS and mRNA levels of SREBP2 but an increase in expression levels of PPARα in the liver. The gene discussed is PPARA; the disease is hyperlipidemia.